In the single-dose cohorts of 240mg and 360mg, briquilimab achieved complete response rates of 89% overall, with substantial reductions in UAS7 scores. How clinically meaningful are these response rates for patients with CSU who fail high-dose antihistamines, and how do they compare to existing biologics in this setting?

Data show that 78% of patients in the single-dose cohorts maintained well-controlled disease through 8 weeks, and 73% of patients in the 180mg Q8W extension achieved complete response at 12 weeks. What does this suggest about the durability of briquilimab’s therapeutic effect and its potential as a long-acting treatment option?

Briquilimab led to rapid and substantial reductions in tryptase levels, with 80% of participants falling below the limit of quantification. How significant is this biomarker change in understanding the drug’s mechanism of action and predicting clinical response in CSU?

The results from the multi-dose cohorts were confounded by an issue with a specific drug product lot. How might this manufacturing setback influence interpretation of efficacy and safety data, and what steps are critical to ensure consistency and reliability in future trials?

Given the strong efficacy observed with single doses and the promising results from the 180mg Q8W regimen, what dosing strategies appear most promising for the planned Phase 2b trial, and how will the additional 10–12 patients being enrolled help refine dose selection?

Briquilimab showed a favorable safety profile, with only mild, reversible decreases in neutrophil counts and no grade 3 or higher treatment-related adverse events. How reassuring are these findings for chronic use in CSU, and what monitoring considerations might clinicians need to adopt?

Jasper is halting development of briquilimab in asthma (ETESIAN trial) and SCID, citing the drug product lot issue and resource reallocation. From a clinical and development perspective, how might focusing solely on CSU improve the program’s likelihood of success?

With Phase 2b initiation now expected in mid-2026, what are the key milestones investors and clinicians should watch for, and how could briquilimab potentially differentiate itself in a competitive CSU biologics market dominated by anti-IgE and anti-IL-4/13 therapies?